Wish to keep on prime of the science and politics driving biotech immediately? Join to get our biotech e-newsletter in your inbox.
Hiya! Right this moment, we discuss how Bernie Sanders may be hitting a wall with the drug business, see a glimmer of potential for HIV vaccines, and introduce a brand new Monday fundraising characteristic.
Additionally, please tell us what you think of The Readout.
The necessity-to-know this morning
- PTC Therapeutics stated the European Fee has requested a re-evaluation of a earlier choice made by European drug regulators to take away its therapy for Duchenne muscular dystrophy, referred to as Translarna, from the market.
- Dyne Therapeutics reported clinical updates on two medicine being developed to deal with myotonic dystrophy sort 1 and Duchenne muscular dystrophy, respectively.
- Rapport Therapeutics, a developer of medicine for neurological ailments, filed for an initial public offering.
Bernie Sanders vs. Novo. Who wins?
Bernie Sanders might lastly be hitting a restrict in his appreciable efforts to badger the pharmaceutical business about excessive drug costs. As the top of a Senate well being committee that focuses on the topic, he’s now demanding that Novo Nordisk reduce costs for its blockbuster GLP-1 medicine. And that appears unlikely.
“There may be completely no purpose to assume that these producers are going to answer Sanders’ criticisms,” one conservative-leaning financial coverage skilled advised STAT’s Rachel Cohrs Zhang.
On a latest investor name, Novo executives stated the total worth of medicines like Ozempic hasn’t been realized but, and that costs would naturally decline as competitors heats up. Sanders just lately wrote an op-ed in a Danish newspaper asking the nation to crack down on Novo Nordisk, and launched a report on how a lot its weight-loss drug would price if extra adults would begin taking it. However the bully pulpit “can’t do all the pieces,” a pricing advocate advised STAT.
Learn extra.
Cytokinetics desires to remain impartial
Cytokinetics CEO Robert Blum is dedicated to independently commercializing aficamten, ought to the center drug obtain approval. Part 3 outcomes confirmed the drug’s efficacy in treating obstructive hypertrophic cardiomyopathy — maybe much more so than the same therapy made by Bristol Myers Squibb, STAT’s Elaine Chen writes. This has led to hypothesis about whether or not the corporate will likely be acquired, or if it can license the medication to bigger pharma gamers which have extra sources.
Talking at a chat throughout STAT’s Breakthrough Summit West, nonetheless, Blum stated the plan stays “to construct a business enterprise. And that’s not one thing new. That’s not one thing that’s the results of a failed M&A dialogue.”
Learn extra.
Animal research present potential for HIV vaccine technique
Resilience and mutability have allowed HIV to dodge efforts to develop an efficient vaccine for many years. However 4 Science research describe new efforts at instructing the immune system — in mice and monkeys — to provide sturdy antibody responses that block many viral strains by exposing them to totally different vaccines.
In a single examine, researchers used engineered proteins to activate specialised B cells in rhesus monkeys in order that they produced antibodies that might latch onto the HIV virus. It’s unclear whether or not these antibodies may truly shield towards an infection and illness — nevertheless it’s an encouraging first step.
“In most vaccines, you’re making an attempt to get a typical antibody response, it’s type of like if there’s a jar of jelly beans and it has one gold — and that’s the one you’re making an attempt to get,” one of many examine’s authors advised STAT. “However for a tough downside like HIV, as an alternative of a jelly bean jar, you’re looking for that one gold jelly bean in a swimming pool.”
Learn extra.
What’s new in fundraising
As a brand new Monday characteristic, we’re highlighting attention-grabbing fundraises we discovered whereas trawling latest SEC filings.
Right here’s one: A stealth Boston-area startup referred to as Progentos Therapeutics has raised a powerful $68.6 million. The CEO on file is Christopher Loose, a Yale entrepreneurship lecturer. Notably, he cofounded MIT spinout Frequency Therapeutics, which targeted on reverse listening to loss, and in addition catheter firm Semprus BioSciences with MIT’s Robert Langer.
Progentos could also be targeted on multiple sclerosis, in line with one other SEC submitting in March — displaying that Progentos acquired the MS program from Frequency Therapeutics, which merged final 12 months with Korro Bio. Free was chief scientific officer of Frequency, which additionally had a preclinical remyelination program underway for a number of sclerosis.
Additionally of curiosity? Seems to be like Breakout Ventures is raising its third fund. We don’t but know the way a lot, however the firm has backed a number of founder-led biotech corporations. Its second fund rolled out in 2021, utilizing its $112.5 million to concentrate on “inventive biosciences startups.” Its first was in 2017, for $60 million.
Extra reads
- Moderna wins Covid shot patent case towards Pfizer-BioNTech in Europe, Reuters
- FDA rejects liver most cancers drug combo, shares of Korean biotech tank, Endpoints
- China is vital marketplace for Singaporean biotech start-up’s abdomen most cancers early prognosis equipment, South China Morning Post